Addex Therapeutics Ltd (ADXN)

Etorro trading 970x250
Addex Therapeutics Ltd (ADXN) Logo

About Addex Therapeutics Ltd

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. to develop mGluR2PAM compounds for the treatment of human health. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland. Address: Chemin des Mines, 9, Geneva, Switzerland, 1202

Addex Therapeutics Ltd News and around…

Latest news about Addex Therapeutics Ltd (ADXN) common stock and company :

Addex Therapeutics Ltd. Sponsored ADR (ADXN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
26 Oct, 2021 Yahoo! Finance

Addex Therapeutics Ltd. Sponsored ADR (ADXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
12 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Addex to Present at the Investors’ Day hosted by Voxia Communication
06 Oct, 2021 Yahoo! Finance

Geneva, Switzerland, October 6, 2021 - Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the Investors’ Day hosted by Voxia Communication (October 7, 2021). The event will take place at the Beau Rivage Hotel in Geneva. In his presentation, which is scheduled for Thursday, October 7, 2021, at 12:10 CEST, Mr Dyer will provide a corporate upd

Addex to Present at the 10th International Meeting on Metabotropic Glutamate Receptors
04 Oct, 2021 Yahoo! Finance

Geneva, Switzerland, October 4, 2021 - Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Dr Lütjens, Head of Discovery – Biology and Dr Rocher, Head of Discovery – Chemistry, will present today at the 10th International Meeting on Metabotropic Glutamate Receptors (October 1 - 6, 2021). Dr Paparin, Senior Manager – Chemistry, will be participating at the conference as well. In a first

The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
29 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA ...

Addex Therapeutics Initiates Phase 2 Clinical Study with Dipraglurant in Blepharospasm
29 Sep, 2021 FinancialContent
Addex to Present at the Cantor Global Healthcare 2021 Conference
29 Sep, 2021 Yahoo! Finance

Geneva, Switzerland, September 29, 2021 - Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the Cantor Global Healthcare 2021 Conference (September 27 - 30, 2021). In his presentation, which is scheduled for Wednesday, September 29, 2021 at 08:00 EDT / 14:00 CEST, Mr Dyer will provide a corporate update and discuss recent developments at Addex. The vide

Addex Therapeutics, CMTA Join Forces To Develop Potential Treatment For Rare Neurological Disorder
22 Sep, 2021 FinancialContent

The Charcot–Marie–Tooth Association (CMTA), a philanthropic funder of CMT research worldwide, andAddex Therapeutics ...

CMTA and Addex Therapeutics Enter Collaboration to Advance GABA B PAM as Potential Treatment for CMT1A
22 Sep, 2021 Yahoo! Finance

Ad Hoc Announcement Pursuant to Art. 53 LR Glenolden, PA and Geneva, Switzerland, September 22, 2021 (GLOBE NEWSWIRE) - The Charcot–Marie–Tooth Association (CMTA), the largest philanthropic funder of CMT research worldwide, and Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced a collaboration to investigate a potential therapy for CMT type 1A (CMT1A), the most common subt

Addex to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
08 Sep, 2021 Yahoo! Finance

Geneva, Switzerland, September 8, 2021 - Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference (September 13 - 15, 2021). In his presentation, which is scheduled for Monday, September 13, 2021 at 07:00 ET / 13:00 CEST, Mr Dyer will provide a corporate update and discuss recent developments at Adde

45 Stocks Moving In Tuesday's Mid-Day Session
07 Sep, 2021 FinancialContent

Gainers IronNet, Inc. (NYSE: IRNT) shares jumped 50.4% to $25.06 after jumping over 23% on Friday. Mechel PAO (NYSE: MTL) shares ...

23 Stocks Moving in Tuesday's Pre-Market Session
07 Sep, 2021 FinancialContent

Gainers IronNet, Inc. (NYSE: IRNT) rose 89.7% to $31.61 in pre-market trading after jumping over 23% on Friday. Mechel PAO ...

Addex to Present at the Swiss Biotech Day
02 Sep, 2021 Yahoo! Finance

Geneva, Switzerland, September 2, 2021 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present a corporate overview at the Swiss Biotech Day, held September 7, 2021 at the Congress Center Basel, Messeplatz 21, 4058 Basel, Switzerland. Mr. Dyer’s presentation is scheduled for 13:15 in room Montreal. If you would like to schedule a meeting with Mr. Dyer, please

Addex Reports 2021 Half Year and Second Quarter Financial Results and Provides Corporate Update
05 Aug, 2021 Yahoo! Finance

Strong cash and cash equivalents position at June 30, 2021 of CHF18.1M ($19.6M)Pivotal dipraglurant PD-LID study initiatedJanssen Pharmaceuticals started Phase 2 study in epilepsy with ADX71149Dipraglurant blepharospasm study on track to start in Q3 2021Completed $11.5M fundraising in January 2021 Geneva, Switzerland, August 5, 2021 - Ad Hoc Announcement Pursuant to Art. 53 LR Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulatio

Earnings Scheduled For August 2, 2021
02 Aug, 2021 FinancialContent

Companies Reporting Before The Bell • HSBC Holdings (NYSE:HSBC) is estimated to report earnings for its second ...

Addex Therapeutics to Release Half-Year 2021 Financial Results and Host Conference Call on August 5, 2021
02 Aug, 2021 Yahoo! Finance

Geneva, Switzerland, August 2, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its Half-Year 2021 financial results on Thursday, August 5, 2021. Tim Dyer, CEO, Roger Mills, CMO and Robert Lütjens, Head of Discovery Biology, will provide a business update and review its pipeline during a teleconference and webcast for investors, analysts and

Addex Appoints Seasoned Pharma Drug Researcher Mikhail Kalinichev as Head of Translational Science
02 Aug, 2021 Yahoo! Finance

Geneva, Switzerland, August 2, 2021 (GLOBE NEWSWIRE) - Ad Hoc Announcement Pursuant to Art. 53 LR Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced the appointment of Mikhail Kalinichev, PhD, as Head of Translational Science. Dr. Kalinichev is a seasoned pharmaceutical R&D professional with more than 20 years of diversified experience at leading pharmaceutical companies and

Addex and Indivior Extend Research Collaboration on GABAB Positive Allosteric Modulators - Indivior Commits $4 Million of New Funding
29 Jul, 2021 Yahoo! Finance

IND enabling studies with Indivior collaboration drug candidate and separate Addex program scheduled for 2022 Geneva, Switzerland, July 29, 2021 (GLOBE NEWSWIRE) - Ad Hoc Announcement Pursuant to Art. 53 LR Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has extended its research collaboration agreement with Indivior PLC (LON: INDV). As part of the extension, Indi

Addex Therapeutics (ADXN) Sees Hammer Chart Pattern: Time to Buy?
16 Jul, 2021 Yahoo! Finance

Addex Therapeutics (ADXN) has been struggling lately, but the selling pressure may be coming to an end soon.

50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021
08 Jul, 2021 Yahoo! Finance

RALEIGH, NC / ACCESSWIRE / July 8, 2021 / Access to Giving - an investor conference themed around investor education and advocacy begins next week, July 13th \- 15th, 2021. More than 50 companies are scheduled to conduct virtual presentations over the three-day period as well as 1x1 meetings with qualified investors throughout the event.

Addex Therapeutics to Present at Access to Giving Virtual Conference on July 14, 2021
07 Jul, 2021 Yahoo! Finance

Geneva, Switzerland, July 7, 2021 - Addex Therapeutics (SIX:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Chief Executive Officer, Tim Dyer, will present at Access to Giving Virtual Conference at 9 AM ET on July 14, 2021. Mr. Dyer will give a corporate update, including an overview of recent advances in Addex’s clinical trial program. The conference is free to all registrants. Registration DetailsDate: W

Addex, Stanford University and University of Copenhagen Publish mGlu2 Structure in Nature Using Addex Allosteric Modulators
01 Jul, 2021 Yahoo! Finance

Ad Hoc Announcement Pursuant to Art. 53 LR Data could enable acceleration of lead optimization using computer aided drug discovery toolsAddex existing mGlu2 positive allosteric modulator, ADX71149, in clinical studies for epilepsy and mGlu2 negative allosteric modulators in preclinical development for neurocognitive disorders Geneva, Switzerland, July 1, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug dis

The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs
30 Jun, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Addex Establishes At-The-Market ADS Equity Sale Program
30 Jun, 2021 Yahoo! Finance

Geneva, Switzerland, June 30, 2021 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that the company has entered into a sales agreement with Cantor Fitzgerald & Co. (Cantor Fitzgerald), acting as sales agent, to offer American Depositary Shares (ADSs), each representing six shares with no nominal value through an “at-the-market” (ATM) offering program. The company’s ADSs are traded on

Addex Therapeutics Starts Mid-Stage Study For Dipraglurant In Parkinson's Associated Dyskinesia
29 Jun, 2021 FinancialContent

Addex Therapeutics Ltd(NASDAQ: ADXN)has started patient screeningfor its Phase 2b/3 study evaluating dipraglurant ...

The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout
29 Jun, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Addex Therapeutics Initiates Pivotal Phase 2b/3 Study with Dipraglurant for Dyskinesia Associated with Parkinson’s Disease
29 Jun, 2021 FinancialContent
Addex Therapeutics Initiates Pivotal Phase 2b/3 Study with Dipraglurant for Dyskinesia Associated with Parkinson’s Disease
29 Jun, 2021 Yahoo! Finance

Geneva, Switzerland, June 29, 2021 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that screening of patients has started for its pivotal Phase 2b/3 study with dipraglurant for dyskinesia associated with Parkinson’s disease (PD-LID). Dyskinesia is believed to be caused by increased glutamatergic neurotransmission. Dipraglurant selectively targets the metabotropic glu

12 Health Care Stocks Moving In Friday's Pre-Market Session
18 Jun, 2021 FinancialContent

Gainers AnPac Bio-Medical Science (NASDAQ:ANPC) stock rose 21.47% to $5.26 during Friday's pre-market session. The ...

Addex Shareholders Approve All Resolutions at Annual General Meeting
17 Jun, 2021 Yahoo! Finance

Geneva, Switzerland, June 17, 2021 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved, with a large majority, all of the proposals of the board of directors in its 2021 Annual General Meeting (AGM). In line with the Swiss Federal Council COVID-19 Ordinance 3, no shareholders attended the AGM in person. The voting proxy represented 39.24% of the company's ou

Addex Therapeutics Ltd (ADXN) is a NASDAQ Common Stock listed in

970x250